Evidence map›Paper›PMID 29296517›Full record

ArticleOncoimmunology

T cell inhibitory mechanisms in a model of aggressive Non-Hodgkin's Lymphoma.

Tamara Hilmenyuk, Carla A Ruckstuhl, Michael Hayoz, Christian Berchtold, Jean-Marc Nuoffer, Shyam Solanki, Hector C Keun, Paul A Beavis, Carsten Riether, Adrian F Ochsenbein

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 52% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 3 countries.

Tamara HilmenyukTumor Immunology, Department of Clinical Research, University of Bern, Bern, Switzerland.
Carla A RuckstuhlTumor Immunology, Department of Clinical Research, University of Bern, Bern, Switzerland.
Michael HayozInstitute of Clinical Chemistry, University Hospital and University of Bern, Bern, Switzerland.
Christian BerchtoldInstitute of Clinical Chemistry, University Hospital and University of Bern, Bern, Switzerland.
Jean-Marc NuofferInstitute of Clinical Chemistry, University Hospital and University of Bern, Bern, Switzerland.
Shyam SolankiDepartment of Surgery and Cancer, Faculty of Medicine, Imperial College London, Exhibition Road, South Kensington, London SW7 2AZ, London, UK.
Hector C KeunDepartment of Surgery and Cancer, Faculty of Medicine, Imperial College London, Exhibition Road, South Kensington, London SW7 2AZ, London, UK.
Paul A BeavisCancer Immunology Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.
Carsten RietherTumor Immunology, Department of Clinical Research, University of Bern, Bern, Switzerland.
Adrian F OchsenbeinTumor Immunology, Department of Clinical Research, University of Bern, Bern, Switzerland.
University of Bern · CHImperial College London · GBThe University of Melbourne · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A reduced immune surveillance due to immune deficiency or treatment with immunosuppressive drugs is associated with a higher risk to develop aggressive Non-Hodgkin's lymphoma (NHL). Nevertheless, NHL also develops in immunocompetent patients indicating an escape from the immune system. T cell function in advanced aggressive lymphoma is not well characterized and the molecular mechanisms how malignant B cells influence T cell function are ill-defined. We therefore studied T cell function in Eμ-myc transgenic mice that develop an aggressive B cell lymphoma with some similarities to human Burkitt-lymphoma (BL). In advanced lymphoma, the number of T cells was severely reduced and the remaining CD4

Indexed as

Aggressive B cell NHL; apoptosis; T lymphocytes; checkpoint inhibition; purine metabolites

Identifiers

PMID29296517
PMCPMC5739580
OpenAlexW2753294829

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.